基孔肯雅热减毒活疫苗IXCHIQ上市后安全性评估
全球约55,900剂接种后报告35例SAE(6.3/万剂),多数发生于有合并症的老年人,监管结论认为总体获益-风险仍有利。
要点
- 全球约55,900剂接种后报告35例SAE(6.3/万剂),多数在接种后7天内发生。
- ≥65岁成人占接种剂次的33%,却占SAE的77%,中位年龄73岁,91%有合并症。
- 监管评估认为IXCHIQ总体获益-风险仍有利,产品信息已更新以强化警告、注意事项和禁忌。
核心结论
- 早期上市后SAE主要发生于有合并症的老年人,符合减毒活疫苗预期反应原性模式。
- 监管审查认为IXCHIQ在授权及国家推荐人群中的总体获益-风险仍有利。
研究设计与样本
- 上市后安全性评估,整合全球药物警戒系统与上市许可持有人收到的SAE数据及主要监管评估。
主要发现
- 截至2025年8月31日全球约55,900剂接种,报告35例SAE(6.3/万剂)。
- ≥65岁成人占接种剂次的33%,占SAE的77%;SAE患者中位年龄73岁,91%有合并症。
- 多数事件发生于接种后7天内,包括全身性基孔肯雅热样反应15例、神经系统13例、心脏3例、肾脏3例。
- 3例死亡均为有合并症的老年男性;1例疫苗株脑炎被认为可能与接种相关。
- 未发现生产或批次相关问题。
关键数值与推荐
- SAE报告35例,相当于6.3/万剂。
- ≥65岁成人占接种剂次33%、占SAE 77%;SAE患者中位年龄73岁,91%有合并症。
- 全身性基孔肯雅热样反应15例、神经系统13例、心脏3例、肾脏3例。
- 监管审查认为IXCHIQ总体获益-风险仍有利,产品信息已更新以强化警告、注意事项和禁忌。
临床怎么用
- 接种前应评估老年人合并症及禁忌证,并参考更新后的产品信息。
- 接种后7天内关注全身性基孔肯雅热样、神经系统、心脏和肾脏相关症状。
- 在授权及国家推荐人群中使用,遵循监管机构更新的警告与注意事项。
局限性
- SAE数据来自被动药物警戒系统,可能存在报告偏倚和不完整。
- 早期接种集中于疫情应对中的老年多病共存人群,可能影响SAE分布的外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IXCHIQ (VLA1553) is a licensed live-attenuated chikungunya vaccine. A post-marketing safety review, including the EU Article 20 referral to the European Medicines Agency (EMA) and its Pharmacovigilance Risk Assessment Committee (PRAC), was initiated following early real-world use during the 2024-2025 La Réunion outbreak. This analysis integrates global serious adverse event (SAE) data with major regulatory assessments to inform clinicians and policymakers. METHODS: Serious adverse events reported from 9 November 2023 to 31 August 2025 were evaluated across major pharmacovigilance systems (EudraVigilance, Vaccine Adverse Event Reporting System, Canada Vigilance, MHRA) and cases received by the marketing authorisation holder (MAH). RESULTS: By 31 August 2025, approximately 55,900 doses had been administered worldwide, yielding 35 SAEs (6.3 per 10,000 doses). One-third of doses (33%) were administered in adults ≥65 years, who accounted for 77% of SAEs, reflecting the older, multimorbid population initially targeted during outbreak response in La Réunion. The median age of persons with SAEs was 73 years; 91% had comorbidities. Most events occurred within 7 days and included systemic chikungunya-like reactions (15), neurological (13), cardiac (3), and renal (3) manifestations. Three fatalities occurred in older men with multimorbidity; one case of vaccine-strain encephalitis was considered probably related to vaccination. No manufacturing or batch-related issues were identified. CONCLUSIONS: Early post-marketing SAEs occurred mainly in older adults with multimorbidity, reflecting reactogenicity patterns expected with live-attenuated vaccines, while serious events were uncommon in adults <65 years relative to doses administered. Regulatory reviews concluded that IXCHIQ's overall benefit-risk balance remains favourable within authorised and nationally recommended populations, and product information was updated to reinforce warnings, precautions, and contraindications.
引用
- Vondeling GT, Croda J, Jelinek T, et al. Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ). Vaccine. 2026. PMID: 41863914. doi:10.1016/j.vaccine.2026.128491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。